# A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

> **NCT04024813** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 1 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Seladelpar
- **DRUG:** Placebo to match Seladelpar

## Key facts

- **NCT ID:** NCT04024813
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-12
- **Primary completion:** 2020-01-09
- **Final completion:** 2020-01-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study was terminated as a precautionary measure due to histological findings in a nonalcoholic steatohepatitis (NASH) study (CB8025-21730, NCT03551522).
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04024813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04024813, "A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04024813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*